Novartis - BUS6900 Wiki

crunchkingofprussiaBiotechnology

Dec 6, 2012 (4 years and 6 months ago)

243 views

Jian

Gu

Sedem

Yener

Elias Jaime
Porras


BUS6900


IP Strategy and Management

NOVARTIS GROUP

Context


About Novartis Company


IP Portfolio


IP strategy and
management


Future plan for Novartis
Company


About Novartis Company


multinational pharmaceutical company


offers a wide range of healthcare products through our
Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer
Health Divisions.


a full member of the European Federation of Pharmaceutical
Industries and Associations.


was created in 1996 from the merger of
Ciba
-
Geigy

and
Sandoz Laboratories
.


Main local is Switzerland.


In 1998 the company made headlines with its biotechnology
licensing agreement with the UC Berkeley Department of Plant
and Microbial Biology.


Details


CEO



:
Dr. Daniel
Vasella
, M.D.


Employees


:

98200


Market Cap

:

107,150,055,000


Auditor


:

PriceWaterHouse Cooperation A.G.


Gross Margin

:

71.3


Profit Margin

:

20.3


EBIT Margin

:

20.9


Return on Equity

:

23.9


Return on Capital:

22.9


Return on Assets

:

14.8

Pharmaceuticals Products of


Novartis Company


Diovan
-

$5.0 B sales

(2007)
-

Hypertension


Gleevec

-

$3.1 B
-

for Chronic myeloid
leukemia


Zometa
-

$1.3 B (2007)
-

Cancer
complications


Sandostatin

-

$1.0 B (2007)
-

Acromegaly


Sandimmun

Neoral
-

$944 M (2007)
-

Transplantation


Femara
-

$937 M (2007)
-

Breast
cancer


Lotrel
-

$748 M (2007)
-

Hypertension


Voltaren
-

$747 M (2007)
-

Inflammation


Trileptal
-

$692 M (2007)
-

Epilepsy


Lescol
-

$665 M (2007)
-

cholestrol



Exelon
-

$632 M (2007)
-

Alzheimer's
disease


Comtan
-

$420 M (2007)
-

Parkinson's
disease


Tegretol
-

$413 M (2007)
-

Epilepsy


Lucentis
-

$393 M (2007)
-

Age
-
related macular degeneration


Ritalin
-

$375 M (2007)
-

ADD


Exjade
-

$357 M (2007)


Iron
chelator


Tobramycin
-

$273 M (2007)
-

Cystic fibrosis


Termalgin

-

(
Paracetamol

and
compounds.)
-

Treatment of fever
and light pain.


Major therapeutic areas:


autoimmunity/transplantation/
inflammatory disease


cardiovascular disease


diabetes


gastrointestinal disease


infectious diseases


musculoskeletal disease


neuroscience


oncology


ophthalmology


respiratory disease

Novartis IP portfolio!!!


involves coordination and
quality control of biologics
patenting and freedom
-
to
-
operate analysis across all
disease areas, platforms,
and functions within NIBR.


is Director of Intellectual
Property


John T. Li

Patents, Head, Biology &
Biologics, Novartis
Institutes for

Biomedical Research

Novartis

Novartis IP portfolio and It’s
Process!!!


operates in 140 countries and currently has 75 new treatments
in the pipeline


More than 12,000 US Granted Patents


Patent Mapping Reports provide specific and detailed insights
into patenting activities of specific Fortune 500, NASDAQ and
S&P

500
organisations


Is gearing up to break new CSR ground, with a funding
proposal for neglected disease research that advantages IP
rights to strike a balance between corporate return on
investment and the provision of vital treatments to penniless
developing countries.

Novartis IP portfolio and It’s Process!!!


The International Patent Classification (IPC) is a hierarchical
system in which the whole area of technology is divided into
a range of sections, classes, subclasses and groups.


have undertaken a concordance (matching) of IPC
(International Patent Classification ) and (US Patent
Classification) UPC to NAICS (North American Industrial
Classification System
-
this new, uniform, industry
-
wide
classification system has been designed as the index for
statistical reporting of all economic activities of the U.S.,
Canada, and Mexico).


Future Planning


Novartis Buys Additional 51.7% Stake in Speedel company.


Make e
-
business partnership: World Online and Novartis
plan together to build initially a pan
-
European portal and an
e
-
commerce platform that will become the first of its kind
within the healthcare and wellness arena.


30% Increase In US Supplies Of Fluvirin Influenza Vaccines
And Delivery Of 40 Million Doses.


will be replaced by two Novartis execs who will oversee
development in newly created roles

Thank you!!!


Any Question?